Alzheimer's Disease: Failed Clinical Trial
Latrepirdine attracted renewed interest in 2009 after being shown in small preclinical trials to have positive effects on persons suffering from Alzheimer’s disease. Animal studies showing potential beneficial effects on Alzheimer's disease models were shown in Russian research in 2000. Preliminary results from human trials have also been promising. In an initial six-month phase II trial, results have shown significant improvement over placebo at 12 months. Latrepirdine showed promising results in a phase III-equivalent, double-blind trial in Russia with mild–moderate stage patients. In April 2009, Pfizer and Medivation initiated a phase III trial (CONCERT study) aiming for FDA approval. In March 2010, Pfizer announced that this clinical trial failed to show any benefit for the treatment of Alzheimer's disease patients.
Numerous phase III trials for AD were recruiting in 2009.
In July 2009, Pfizer and Medivation announced that "latrepirdine" will be the proposed international nonproprietary name for latrepirdine for the treatment of Alzheimer's.
In March 2010, the results of a clinical trial phase III were released; the investigational Alzheimer's disease drug dimebon failed in the pivotal CONNECTION trial of patients with mild-to-moderate disease.
Famous quotes containing the words trial and/or failed:
“I have proved by actual trial that a letter, that takes an hour to write, takes only about 3 minutes to read!”
—Lewis Carroll [Charles Lutwidge Dodgson] (18321898)
“The situation of our youth is not mysterious. Children have never been very good at listening to their elders, but they have never failed to imitate them. They must, they have no other models.”
—James Baldwin (19241987)